After the SELECT trial cardiovascular indication for Wegovy (FDA approved March 2024) and the SURMOUNT-OSA approval for Zepbound (December 2024), Aetna added separate coverage pathways for those medical indications, which often bypass the obesity carve-outs
Abbott's medical device segment grew 14.8% to $5.45 billion
MatthewsDRDejagerSAhrenBFonsecaVFerranniniECouturierAet al
I actually think its a problem a lot of other women can relate to, that you are in the gym and eating healthy, but just cant get to the level you want or need to," Williams said
The Saxenda Spin-Off: Another Weight Management Star While Ozempic and Wegovy have garnered much attention, let's not forget another GLP-1 receptor agonist family member that's been turning heads in the weight management world for years now: Saxenda (liraglutide)
For example, camelid antibodies (Hamers-Casterman et al, 1993